ReviewToxins2019
Antibodies and Vaccines against Botulinum Toxins: Available Measures and Novel Approaches.
Review in Toxins, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 58 citations in OpenAlex.
- Development of novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid derivatives for inhibiting the catalytic activity of botulinum neurotoxins type B and F: in silico, in vitro & in vivo evaluation.Archives of toxicology · 2026Article
- Nebulization of an mRNA-encoded monoclonal antibody for passive immunization of foals against Rhodococcus equi.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Dual-Toxin-ProducingToxins · 2025Article
- Development and Functional Characterization of Monoclonal Antibodies for Botulinum Neurotoxin Serotype A.Foods (Basel, Switzerland) · 2025Article
- Recombinant expression of receptor binding domains of all eight subtypes of botulinum neurotoxin type A for generation of antitoxins with broad reactivity.F1000Research · 2025Article
- Antibody-based alternatives to animal testing for toxin detection and antitoxin evaluation.Frontiers in toxicology · 2025Review
- Passive Immunisation in the Treatment of Infectious Diseases Related to Highly Potent Bacterial Toxins.Biomedicines · 2024Review
- Neutralizing chimeric heavy-chain antibody targeting the L-HN domain of Clostridium botulinum neurotoxin type F.Archives of toxicology · 2024Article
- A genetically engineered neuronal membrane-based nanotoxoid elicits protective immunity against neurotoxins.Bioactive materials · 2024Article
- Review
- Selection of Candidate Monoclonal Antibodies for Therapy of Botulinum Toxin Type A Intoxications.Toxins · 2024Article
- New approach to generating of human monoclonal antibodies specific to the proteolytic domain of botulinum neurotoxin A.BioImpacts : BI · 2024Article
- A DARPin promotes faster onset of botulinum neurotoxin A1 action.Nature communications · 2023Article
- Pathogenicity and virulence ofVirulence · 2023Review
- Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines.Toxins · 2023Review
- Botulism in Cattle: A Case Report of an Outbreak in Sardinia (Italy).Animals : an open access journal from MDPI · 2023Article
- Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs.Applied microbiology and biotechnology · 2023Article
- Biological and Immunological Characterization of a Functional L-HN Derivative of Botulinum Neurotoxin Serotype F.Toxins · 2023Article
- Development and evaluation of a tetravalent botulinum vaccine.Human vaccines & immunotherapeutics · 2022Article
- Natural toxins and One Health: a review.Science in One Health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum neurotoxin (BoNT) is produced by the anaerobic, Gram-positive bacterium
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.